Hydrophilic Microspheres for Sustained Hydrophobic Drug Release

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current drug delivery systems face challenges in achieving sustained and non-burst release of hydrophobic drugs like paclitaxel and rapamycin, particularly in hydrophobic polymer systems, due to poor compatibility and rapid initial drug release, which limits their effectiveness in embolization therapy for tumors.

Innovation Solution

A new process for forming drug-loaded hydrophilic microspheres involves contacting water-insoluble, hydrophilic polymer particles with a drug solution in an aprotic solvent, followed by precipitation and rinsing to create a homogeneous core with a drug-rich interior and a thin surface layer, ensuring controlled release and stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If hydrophobic polymer systems are used to deliver hydrophobic drugs, then drug solubility is improved, but rapid initial drug release (burst release) occurs

Engineering Contradiction:
Improvedrug solubilityVSAvoidrelease duration
Core Design Contradiction:
Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent changes the fundamental parameter of polymer hydrophobicity to hydrophilicity, using hydrophilic polymers (polyvinyl alcohol, polyacrylamide, gelatin, collagen, chitosan) to deliver hydrophobic drugs. This parameter change prevents burst release while maintaining drug solubility through the unique mechanism of drug precipitation within the hydrogel matrix during water absorption, enabling sustained release over days to weeks.

Inventive Principle:
Principle #35Parameter changes

2Duration of action of moving object

If hydrophilic polymer systems are used to deliver hydrophobic drugs, then sustained release is improved, but drug compatibility is worsened

Engineering Contradiction:
Improverelease durationVSAvoiddrug-polymer compatibility
Core Design Contradiction:
Duration of action of moving objectVSStability of the object's composition

Solution Approach 1:

The patent exploits phase transition of the hydrophobic drug from dissolved state in organic solvent to precipitated state within the hydrogel matrix upon water absorption. The drug transitions from being soluble in the organic crosslinking agent during formulation to precipitating as fine crystals within the hydrogel network when exposed to aqueous environment, providing stable long-term retention and sustained release without degradation.

Inventive Principle:
Principle #36Phase transitions

3Stability of the object's composition

If organic crosslinking agents are used in hydrogel formation, then gel structure stability is improved, but residual solvent toxicity is worsened

Engineering Contradiction:
Improvegel structure stabilityVSAvoidsolvent toxicity
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent employs volatile organic crosslinking agents (dioxane, ethyl acetate, acetone) that completely evaporate during the drying process, leaving no residual toxic solvent in the final product. These short-living solvents provide temporary structural support during gel formation but are completely removed before implantation, eliminating toxicity concerns while maintaining gel stability.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

4Manufacturing precision

If drug is loaded uniformly throughout the polymer matrix, then drug distribution is improved, but surface drug release is worsened

Engineering Contradiction:
Improvedrug distribution uniformityVSAvoidburst release
Core Design Contradiction:
Manufacturing precisionVSObject-generated harmful factors

Solution Approach 1:

The patent creates local quality differentiation through drug precipitation within the hydrogel matrix. The drug is uniformly distributed during formulation but locally precipitates in specific regions within the gel network upon water absorption, creating zones of high drug concentration embedded within the gel structure. This local precipitation prevents surface-level drug availability and eliminates burst release while maintaining overall uniform distribution.

Inventive Principle:
Principle #3Local quality

Data Source

PatentEP2520287B1Loading of hydrophobic drugs into hydrophilic polymer delivery systems
Publication Date: 2025.03.26 BOSTON SCI MEDICAL DEVICE LTD
  • EP2520287B1 patent drawingFigure 1
  • EP2520287B1 patent drawingFigure 2~3D
  • EP2520287B1 patent drawingFigure 4

AI summary

A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen.